Novel antitumoral use of cabazitaxel

Abstract

The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

What is claimed is: 
     
         1 . A method of reducing the risk of neutropenia complications in a patient with prostate cancer being treated a compound of formula: 
       
         
           
           
               
               
           
         
       
       which may be in base form or in the form of a hydrate or a solvate; 
       comprising monitoring blood counts in the patient at regular intervals during treatment of the patient; reducing the dose of the compound if the patient experiences febrile neutropenia or prolonged neutropenia; discontinuing the treatment if the patient's neutrophil count is ≦1,500 cells/mm 3 ; and optionally restarting the treatment when the patient's neutrophil counts recover to a level ≧1,500 cells/mm 3 . 
     
     
         2 . The method according to  claim 1 , further comprising administering G-CSF to a patient prior to the compound administration, wherein said patient is considered to be at increased risk for neutropenia complications.